Insider Transactions in Q4 2021 at Fate Therapeutics Inc (FATE)
Insider Transaction List (Q4 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 20
2021
|
Edward J Dulac Iii Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
15,977
-12.64%
|
$958,620
$60.0 P/Share
|
|
Dec 20
2021
|
Edward J Dulac Iii Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,437
+10.25%
|
$505,295
$35.52 P/Share
|
|
Dec 13
2021
|
Bahram Valamehr Chief R&D Officer |
SELL
Open market or private sale
|
Direct |
25,000
-2.91%
|
$1,175,000
$47.61 P/Share
|
|
Dec 13
2021
|
Bahram Valamehr Chief R&D Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+12.09%
|
$50,000
$2.73 P/Share
|
|
Dec 10
2021
|
Yu Waye Chu Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,500
-0.82%
|
$390,000
$52.42 P/Share
|
|
Dec 10
2021
|
Yu Waye Chu Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+5.33%
|
$120,000
$16.32 P/Share
|
|
Nov 19
2021
|
Yu Waye Chu Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
60,958
+32.65%
|
-
|
|
Nov 19
2021
|
Edward J Dulac Iii Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
59,540
+34.72%
|
-
|
|
Nov 19
2021
|
Mark Plavsic Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
59,540
+37.9%
|
-
|
|
Nov 19
2021
|
Cindy Tahl General Counsel and Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
60,958
+26.51%
|
-
|
|
Nov 19
2021
|
Bahram Valamehr Chief R&D Officer |
BUY
Grant, award, or other acquisition
|
Direct |
60,958
+28.01%
|
-
|
|
Nov 19
2021
|
J Scott Wolchko President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
86,475
+15.26%
|
-
|
|
Nov 18
2021
|
J Scott Wolchko President and CEO |
SELL
Open market or private sale
|
Direct |
20,000
-4.83%
|
$1,080,000
$54.27 P/Share
|
|
Nov 18
2021
|
J Scott Wolchko President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+4.61%
|
$40,000
$2.7 P/Share
|
|
Oct 22
2021
|
J Scott Wolchko President and CEO |
SELL
Open market or private sale
|
Direct |
30,000
-7.08%
|
$1,740,000
$58.88 P/Share
|
|
Oct 22
2021
|
J Scott Wolchko President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+2.35%
|
$90,000
$3.42 P/Share
|
|
Oct 21
2021
|
J Scott Wolchko President and CEO |
SELL
Open market or private sale
|
Direct |
30,000
-3.6%
|
$1,800,000
$60.23 P/Share
|
|
Oct 21
2021
|
J Scott Wolchko President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+6.61%
|
$60,000
$2.73 P/Share
|
|
Oct 01
2021
|
Cindy Tahl General Counsel and Secretary |
SELL
Open market or private sale
|
Direct |
50,000
-11.87%
|
$2,900,000
$58.89 P/Share
|
|
Oct 01
2021
|
Cindy Tahl General Counsel and Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+24.03%
|
$300,000
$6.55 P/Share
|